The MALT1 is a critical regulator of cytokine and antigen receptor signaling, and MALT1 inhibitors attenuate the pathology of rheumatoid arthritis, ulcerative colitis, lymphomas, spondylitis, autoimmunity, multiple sclerosis, etc. [17–21]. This evidence concerns the gene MALT1 and lymphoma.